تخطي إلى التنقل الرئيسي
تخطي إلى البحث
تخطي إلى المحتوى الرئيسي
الصفحة الرئيسية
المساعدة والأسئلة الشائعة
English
العربية
الصفحة الرئيسية
الوحدات البحثية
الملفات الشخصية
نتاج البحث
المشاريع
المعدات
أنشطة
مجموعات البيانات
الصحافة / وسائل الإعلام
الجوائز
التأثيرات
الدورات التدريبية
البحث حسب الخبرة أو الاسم أو الانتماء
Significance of the Prolactin Receptor in Glioblastoma
Al Kharusi, Amira
(PI)
Medicine And Health Sciences
المشروع
:
Other project
معاينة
بصمة
بصمة
استكشف موضوعات البحث التي تناولها هذا المشروع. يتم إنشاء هذه الملصقات بناءً على الجوائز/المنح الأساسية. فهما يشكلان معًا بصمة فريدة.
فرز حسب
الوزن
أبجديًا
Keyphrases
Glioblastoma
100%
Prolactin Receptor
100%
Tumor
60%
Rapamycin
53%
Mammalian Target of Rapamycin (mTOR)
33%
Angiogenesis
26%
MTOR Pathway
26%
JAK-STAT
20%
Brain Tumor
20%
Immune Suppressant
13%
Paracrine
13%
In Cancer
13%
Tumor Metastasis
13%
Glioblastoma Therapy
13%
Tumor Treatment
13%
Receptor Internalization
13%
Cervical Cancer
13%
Drug Use
13%
Established Drugs
13%
Tumor Progression
13%
TSC1
13%
Induced Growth
13%
Clinical Drugs
13%
Antiangiogenic Factors
13%
Epidermal Growth Factor Receptor
13%
Glioblastoma Cells
13%
Overactivity
13%
Growth Inhibition
13%
Recombinant Protein
13%
Growth Signaling
13%
Local Production
13%
Cancer Treatment
13%
Tuberous Sclerosis Complex
13%
Surgical Intervention
6%
Combination Therapy
6%
Intracranial Tumor
6%
Cancer Development
6%
Survival Response
6%
Screening Program
6%
Primary Brain Tumor
6%
During Pregnancy
6%
Cell Growth
6%
Tumor Cell Proliferation
6%
Epidermal Growth Factor Receptor Inhibitors
6%
Receptor Signaling
6%
Human Breast Cancer
6%
GH Family
6%
Angiogenic Inhibitors
6%
Colon Cancer
6%
Vascular Endothelial Growth Factor Receptor (VEGFR)
6%
Neovascularization
6%
Self-sufficiency
6%
Glioblastoma multiforme
6%
HPV16
6%
Human Ovarian Cancer Cell
6%
Smooth muscle Tumor
6%
Cell Differentiation
6%
SOCS1
6%
Intracellular Protein
6%
Breast Cancer Prognosis
6%
Pro-survival
6%
Phosphoinositide 3-kinase (PI3K)
6%
Colorectal Cancer
6%
Clinical Samples
6%
Myometrium
6%
High-risk Human Papillomavirus (HR-HPV)
6%
Angiogenic Factors
6%
Vascularization
6%
Combined Application
6%
New Vessels
6%
Allelic Loss
6%
Endostatin
6%
Tuberous Sclerosis
6%
Tumor Suppressor
6%
Chromosome 10
6%
Primary Glioblastoma
6%
Tensin Homolog
6%
Ink4a
6%
Autocrine Action
6%
Sequential Expression
6%
Tumoral
6%
Clinical Screening
6%
Biallelic
6%
Patient Survival
6%
Cell Signaling Molecules
6%
Malignant Glioma
6%
Cytotoxic Therapy
6%
Uterine Leiomyoma
6%
Suppressor of Cytokine Signaling 3 (SOCS3)
6%
Recurrent Glioblastoma
6%
Overproduction
6%
Mouse Placenta
6%
Tumor Pathogenesis
6%
Oncogenic Signaling
6%
Cell Studies
6%
Median Survival
6%
Lactogenic Hormones
6%
Papillomavirus Infections
6%
Animal Data
6%
Phosphatase
6%
Human Cytomegalovirus Infection
6%
Cytokine Production
6%
SOCS2
6%
Antigrowth
6%
Platelets
6%
Tumor Growth
6%
Salivary Gland Tumor
6%
Genetic mutation
6%
Cancer Hallmarks
6%
New Therapeutics
6%
Cancer Causes
6%
Prolactin
6%
Hepatocellular Cancer
6%
Hormone Action
6%
Viral Infection
6%
Apoptotic Mechanism
6%
Rhabdomyosarcoma
6%
Chemical Exposure
6%
Role in Cancer
6%
Tumor Cells
6%
Prostate Cancer
6%
Human Cancer
6%
Growth Factors
6%
Breast Cancer
6%
Neuroblastoma Tumor
6%
Human Malignancies
6%
High Risk
6%
INIS
glioblastomas
100%
prolactin
100%
receptors
100%
tumors
100%
cancer
73%
humans
47%
growth
39%
drugs
34%
proteins
30%
blocking
26%
pathogenesis
17%
angiogenesis
17%
brain
17%
levels
17%
signals
13%
patients
13%
production
13%
breasts
13%
hormones
13%
growth factors
13%
connections
8%
slowdown
8%
metastases
8%
therapy
8%
losses
8%
genetics
8%
mutations
8%
proliferation
8%
tumor cells
8%
Medicine and Dentistry
Prolactin Receptor
100%
Glioblastoma
100%
Neoplasm
45%
Mammalian Target of Rapamycin
40%
Malignant Neoplasm
36%
Rapamycin
36%
Tumor Progression
18%
Angiogenesis
18%
Receptor
18%
Brain Tumor
18%
Breast Cancer
13%
Metastatic Carcinoma
9%
Proliferin
9%
Cervical Cancer
9%
Antiangiogenic
9%
Prolactin
9%
Immunosuppressive Drug
9%
Recombinant Protein
9%
Angiogenic Factor
9%
Cancer Therapy
9%
Cancer Treatment
9%
Target Cell
9%
Internalization
9%